Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2014

Open Access 01-12-2014 | Research article

Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia

Authors: Yu Ma, Ziwei Liao, Yi Xu, Ziyun Zhong, Xu Wang, Fan Zhang, Shaohua Chen, Lijian Yang, Gengxin Luo, Xin Huang, Suming Huang, Xiuli Wu, Yangqiu Li

Published in: European Journal of Medical Research | Issue 1/2014

Login to get access

Abstract

Background

Knowledge of the oncogenic signaling pathways of T-cell acute lymphoblastic leukemia (T-ALL) remains limited. Constitutive aberrant activation of the nuclear factor kappa B (NF-κB) signaling pathway has been detected in various lymphoid malignancies and plays a key role in the development of these carcinomas. The zinc finger-containing protein, A20, is a central regulator of multiple NF-κB-activating signaling cascades. A20 is frequently inactivated by deletions and/or mutations in several B-and T-cell lymphoma subtypes. However, few A20 mutations and polymorphisms have been reported in T-ALL. Thus, it is of interest to analyze the expression characteristics of A20 and its regulating factors, including upstream regulators and the CBM complex, which includes CARMA1, BCL10, and MALT1.

Methods

The expression levels of CARMA1, BCL10, MALT1, A20, and NF-κB were detected in peripheral blood mononuclear cells (PBMCs) from 21 patients with newly diagnosed T-ALL using real-time PCR, and correlations between the aberrant expression of these genes in T-ALL was analyzed. Sixteen healthy individuals, including 10 males and 6 females, served as controls.

Results

Significantly lower A20 expression was found in T-ALL patients (median: 4.853) compared with healthy individuals (median: 8.748; P = 0.017), and significantly increased expression levels of CARMA1 (median: 2.916; P = 0.034), BCL10 (median: 0.285; P = 0.033), and MALT1 (median: 1.201; P = 0.010) were found in T-ALL compared with the healthy individuals (median: 1.379, 0.169, and 0.677, respectively). In contrast, overexpression of NF-κB (median: 0.714) was found in T-ALL compared with healthy individuals (median: 0.335; P = 0.001). A negative correlation between the MALT1 and A20 expression levels and a positive correlation between CARMA1 and BCL10 were found in T-ALL and healthy individuals. However, no negative correlation was found between A20 and NF-κB and the MALT1 and NF-κB expression level in the T-ALL group.

Conclusions

We characterized the expression of the CARMA-BCL10-MALT1-A20-NF-κB pathway genes in T-ALL. Overexpression of CARMA-BCL10-MALT in T-ALL may contribute to the constitutive cleavage and inactivation of A20, which enhances NF-κB signaling and may be related to T-ALL pathogenesis.
Appendix
Available only for authorised users
Literature
1.
Aifantis I, Raetz E, Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008, 8: 380–390. 10.1038/nri2304PubMedCrossRef
2.
Morris JC, Waldmann TA, Janik JE: Receptor-directed therapy of T-cell leukemias and lymphomas. J Immunotoxicol 2008, 5: 235–248. 10.1080/15476910802129661PubMedCrossRef
3.
Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004, 350: 1535–1548. 10.1056/NEJMra023001PubMedCrossRef
4.
Zheng H, Wang X, Ma Y, Xu B, Chen S, Yang L, Wu X, Przybylski GK, Huang S, Ye T, Li Y: The TCR gammadelta repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant Vdelta1 and Vdelta2 T cells. DNA Cell Biol 2014, 33: 49–56. 10.1089/dna.2013.2199PubMedPubMedCentralCrossRef
5.
Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, Scheucher PS, Oliveira LC, Dalmazzo LF, Silva-Junior WA, Falcao RP, Rego EM: Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol 2013, 2: 10.
6.
Chen S, Huang X, Zheng H, Geng S, Wu X, Yang L, Weng J, Du X, Li Y: The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation. Mol Cancer 2013, 12: 73.
7.
Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006, 107: 4500–4507. 10.1182/blood-2005-09-3801PubMedCrossRef
8.
Vanura K, Vrsalovic MM, Le T, Marculescu R, Kusec R, Jager U, Nadel B: V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia. Genes Chromosomes Cancer 2009, 48: 725–736. 10.1002/gcc.20677PubMedCrossRef
9.
Lin C, Zheng H, Wang C, Yang L, Chen S, Li B, Zhou Y, Tan H, Li Y: Mutations increased overexpression of Notch1 in T-cell acute lymphoblastic leukemia. Cancer Cell Int 2012, 12: 13.
10.
Zou J, Li P, Lu F, Liu N, Dai J, Ye J, Qu X, Sun X, Ma D, Park J, Ji C: Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol 2013, 6: 3.
11.
Liu N, Zhang J, Ji C: The emerging roles of Notch signaling in leukemia and stem cells. Biomark Res 2013, 1: 23.
12.
Patel B, Kang Y, Cui K, Litt M, Riberio MS, Deng C, Salz T, Casada S, Fu X, Qiu Y, Zhao K, Huang S: Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia. Leukemia 2014, 28: 349–361. 10.1038/leu.2013.158PubMedCrossRef
13.
Huang X, Du X, Li Y: The role of BCL11B in hematological malignancy. Exp Hematol Oncol 2012, 1: 22.
14.
Chen Y, Liu S, Shen Q, Zha X, Zheng H, Yang L, Chen S, Wu X, Li B, Li Y: Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells. DNA Cell Biol 2013, 32: 573–581. 10.1089/dna.2013.2138PubMedPubMedCentralCrossRef
15.
Thome M: Multifunctional roles for MALT1 in T-cell activation. Nat Rev Immunol 2008, 8: 495–500. 10.1038/nri2338PubMedCrossRef
16.
Zhang F, Yang L, Li Y: The role of A20 in the pathogenesis of lymphocytic malignancy. Cancer Cell Int 2012, 12: 44.
17.
Braun FC, Grabarczyk P, Mobs M, Braun FK, Eberle J, Beyer M, Sterry W, Busse F, Schroder J, Delin M, Przybylski GK, Schmidt CA: Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sezary syndrome. Leukemia 2011, 25: 1494–1501. 10.1038/leu.2011.101PubMedCrossRef
18.
Chanudet E, Huang Y, Zeng N, Streubel B, Chott A, Raderer M, Du MQ: TNFAIP3 abnormalities in MALT lymphoma with autoimmunity. Br J Haematol 2011, 154: 535–539. 10.1111/j.1365-2141.2011.08624.xPubMedCrossRef
19.
Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, Asakura Y, Muto S, Tamura A, Iio M, Akatsuka Y, Hayashi Y, Mori H, Igarashi T, Kurokawa M, Chiba S, Mori S, Ishikawa Y, Okamoto K, Tobinai K, Nakagama H, Nakahata T, Yoshino T, Kobayashi Y, Ogawa S: Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459: 712–716. 10.1038/nature07969PubMedCrossRef
20.
Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L: Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459: 717–721. 10.1038/nature07968PubMedPubMedCentralCrossRef
21.
Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M: TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009, 114: 2467–2475. 10.1182/blood-2008-12-194852PubMedCrossRef
22.
Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, Pasqualucci L, Bhagat G, Bertoni F: The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009, 113: 4918–4921. 10.1182/blood-2008-08-174110PubMedPubMedCentralCrossRef
23.
Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, Stanelle J, Siebert R, Kuppers R: TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009, 206: 981–989. 10.1084/jem.20090528PubMedPubMedCentralCrossRef
24.
Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R: T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008, 9: 263–271. 10.1038/ni1561PubMedCrossRef
25.
Zhu L, Zhang F, Shen Q, Chen S, Wang X, Wang L, Yang L, Wu X, Huang S, Schmidt CA, Li Y: Characteristics of A20 gene polymorphisms in T-cell acute lymphocytic leukemia. Hematology 2014, Epub ahead of print.
26.
Ruland J, Duncan GS, Wakeham A, Mak TW: Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003, 19: 749–758. 10.1016/S1074-7613(03)00293-0PubMedCrossRef
27.
Li S, Yang X, Shao J, Shen Y: Structural insights into the assembly of CARMA1 and BCL10. PLoS One 2012, 7: e42775.
28.
29.
Wang X, Xu Y, Liang L, Xu Y, Wang C, Wang L, Chen S, Yang L, Wu X, Li B, Luo G, Tan H, Li W, Li Y: Abnormal expression of A20 and its regulated genes in peripheral blood from patients with lymphomas. Cancer Cell Int 2014, 14: 36.
30.
Shi L, Chen S, Lu Y, Wang X, Xu L, Zhang F, Yang L, Wu X, Li B, Li Y: Changes in the MALT1-A20-NF-kappaB expression pattern may be related to T cell dysfunction in AML. Cancer Cell Int 2013, 13: 37.
31.
Vereecke L, Beyaert R, van Loo G: The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30: 383–391. 10.1016/j.it.2009.05.007PubMedCrossRef
32.
Fontan L, Melnick A: Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. Clin Cancer Res 2013, 19: 6662–6668. 10.1158/1078-0432.CCR-12-3869PubMedCrossRef
33.
Bidere N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, Davis RE, Lenz G, Anderson DE, Arnoult D, Vazquez A, Sakai K, Zhang J, Meng Z, Veenstra TD, Staudt LM, Lenardo MJ: Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature 2009, 458: 92–96. 10.1038/nature07613PubMedPubMedCentralCrossRef
34.
Lin X, Wang D: The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. Semin Immunol 2004, 16: 429–435. 10.1016/j.smim.2004.08.022PubMedCrossRef
35.
Fujiwara SI, Yamashita Y, Nakamura N, Choi YL, Ueno T, Watanabe H, Kurashina K, Soda M, Enomoto M, Hatanaka H, Takada S, Abe M, Ozawa K, Mano H: High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays. Leukemia 2008, 22: 1891–1898. 10.1038/leu.2008.191PubMedCrossRef
36.
Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC: Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol 2014, 21: e573-e603. 10.3747/co.21.1798PubMedPubMedCentralCrossRef
37.
Chaoui D, Bouallegue S, Arakelyan N, Genet P, Aljijakli A, Sutton L: Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma. Br J Haematol 2014, 164: 750–752. 10.1111/bjh.12678PubMedCrossRef
38.
Yu P, Petrus MN, Ju W, Zhang M, Conlon KC, Nakagawa M, Maeda M, Bamford RN, Waldmann TA: Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model. Leukemia 2014, Epub ahead of print.
39.
Mc Guire C, Elton L, Wieghofer P, Staal J, Voet S, Demeyer A, Nagel D, Krappmann D, Prinz M, Beyaert R, van Loo G: Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. J Neuroinflammation 2014, 11: 124.
40.
Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, Wu H, Melnick A: MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012, 22: 812–824. 10.1016/j.ccr.2012.11.003PubMedPubMedCentralCrossRef
41.
Malinverni C, Unterreiner A, Staal J, Demeyer A, Galaup M, Luyten M, Beyaert R, Bornancin F: Cleavage by MALT1 induces cytosolic release of A20. Biochem Biophys Res Commun 2010, 400: 543–547. 10.1016/j.bbrc.2010.08.091PubMedCrossRef
42.
Zhao Y, Huang H, Wei G: Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol 2013, 6: 40.
Metadata
Title
Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia
Authors
Yu Ma
Ziwei Liao
Yi Xu
Ziyun Zhong
Xu Wang
Fan Zhang
Shaohua Chen
Lijian Yang
Gengxin Luo
Xin Huang
Suming Huang
Xiuli Wu
Yangqiu Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2014
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-014-0062-8

Other articles of this Issue 1/2014

European Journal of Medical Research 1/2014 Go to the issue

Research

Construction of microRNA and transcription factor regulatory network based on gene expression data in cardiomyopathy

Case report

Renal artery stenosis due to neurofibromatosis type 1: case report and literature review

Research

The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas

Research

RETRACTED ARTICLE: Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis

Research

Association of methylenetetrahytrofolate reductase (MTHFR) C677T and A1298C polymorphisms with the susceptibility of childhood acute lymphoblastic leukaemia (ALL) in Chinese population

Research

Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model